Nitrofurantoin enteric-coated tablets

This product is an antibacterial drug. Escherichia coli is mostly sensitive to this product, and some strains of Enterobacteriaceae such as Enterobacter aerogenes, Enterobacter cloacae, Proteus, and Klebsiella are sensitive to this product. Pseudomonas aeruginosa is usually resistant to this product. This product has antibacterial effects on Gram-positive bacteria such as Enterococcus. The antibacterial activity of this product is not affected by pus and tissue decomposition products. It is more active in acidic urine. The antibacterial mechanism is to interfere with the oxidoreductase system in the bacteria, thereby blocking its metabolic process.

Molecular weight: C8H6N4O5

This product is an enteric sugar-coated tablet, which appears yellow after removing the coating.

It is used for acute simple lower urinary tract infections caused by sensitive bacteria such as Escherichia coli, Enterococcus, Staphylococcus, Klebsiella, Enterobacter, etc., and can also be used for the prevention of urinary tract infections.

Oral administration, 0.8-1.6g (2-4 tablets) each time, 3 times a day, 4-8 weeks as a course of treatment. The dosage for children is halved.

1. Gastrointestinal reactions such as nausea, vomiting, anorexia and diarrhea are common. 2. Allergic reactions such as rash, drug fever, granulocytopenia, hepatitis, etc. may also occur. Hemolytic anemia may occur in patients with glucose-6-phosphate dehydrogenase deficiency. 3. Adverse reactions of the nervous system such as headache, dizziness, drowsiness, myalgia, nystagmus, etc. may occasionally occur. Most of them are reversible. In severe cases, peripheral neuritis may occur. Patients with existing renal dysfunction or long-term use of this product are more likely to develop this disease. 4. Nitrofurantoin may occasionally cause acute pneumonia symptoms such as fever, cough, chest pain, lung infiltration and eosinophilia, which may disappear quickly after discontinuation of the drug. Corticosteroids may alleviate symptoms in severe patients. Patients who take the drug for more than 6 months may occasionally develop interstitial pneumonia or pulmonary fibrosis. The drug should be discontinued as soon as possible and appropriate treatment measures should be taken.

It is contraindicated for newborns, full-term pregnant women, patients with impaired renal function and patients allergic to furan drugs.

Precautions for children: It is contraindicated for newborns under 1 month old. Precautions for pregnancy and lactation: 1. Because nitrofurantoin can pass through the placental barrier and the fetal enzyme system is not fully developed, it is not suitable for pregnant women in the late pregnancy and is contraindicated for pregnant women at full term to avoid the possibility of hemolytic anemia in the fetus. 2. A small amount of nitrofurantoin can enter breast milk and induce hemolytic anemia in infants, especially those with glucose-6-phosphate dehydrogenase deficiency. Breastfeeding should be stopped when taking this product. Precautions for the elderly: Elderly patients should use it with caution and the dosage should be adjusted according to renal function.

1. When drugs that can cause hemolysis are used in combination with nitrofurantoin, the hemolytic reaction may be increased. 2. When used in combination with hepatotoxic drugs, the hepatotoxic reaction may be increased; when used in combination with neurotoxic drugs, the neurotoxicity may be increased. 3. Both probenecid and sulfinpyrazone can inhibit the renal tubular secretion of nitrofurantoin, resulting in an increase in the latter's blood concentration and (or) a prolonged serum half-life, while the urine concentration is reduced and the efficacy is also weakened. The dosage of probenecid and the like should be adjusted.

Keep away from light and store in sealed container.

50mg

24 months

Yichang Humanwell Pharmaceutical Co., Ltd.

• Founded in:

  2001-08-08

• Address:

  No. 19, Dalian Road, Yichang Development Zone, Hubei Province

• Tax NO.:

  91420500730843405M

• Registered Funds:

  293,527,036 yuan

• Website:

  Log in to view

• Email:

  Log in to view